Chlamydia Infection Diagnostics Market - Global Industry Size, Share, Trends, Opportunity, and Forecast, Segmented By Test Type (Culture Test, Nucleic Acid Amplification Test (NAAT), Direct Fluorescent Antibody Test, Serology Test and Other), By Type of Infections (Genital Chlamydia Infection, Rectal Chlamydia Infection, Ocular Chlamydia Infection), By End User (Hospitals, Specialty Clinics, Diagnostics Centre), By Region and Competition, 2020-2030F

Market Overview

The Global Chlamydia Infection Diagnostics Market was valued at USD 721.33 Million in 2024 and is expected to reach USD 1031.67 Million by 2030 with a CAGR of 6.12%. Chlamydia infection is one of the most prevalent sexually transmitted infections (STIs) worldwide, caused by the bacteria Chlamydia trachomatis. Left untreated, it can lead to serious health complications, including pelvic inflammatory disease, infertility, and increased susceptibility to other STIs. Timely and accurate diagnosis is crucial to prevent these adverse outcomes. The Chlamydia Infection Diagnostics Market has witnessed significant advancements in recent years, offering more effective and convenient diagnostic tools that empower healthcare providers and individuals to combat this silent epidemic. Chlamydia is a silent infection, often presenting with no noticeable symptoms. This characteristic, coupled with the stigma surrounding STIs, leads to underdiagnosis and undertreatment. According to the World Health Organization (WHO), an estimated 131 million new cases of chlamydia occurred globally in 2020, making it one of the most commonly reported bacterial STIs. The burden is particularly high among sexually active young individuals, with the age group of 15 to 24 being the most affected. Traditionally, the gold standard for diagnosing chlamydia infections has been nucleic acid amplification tests (NAATs), such as polymerase chain reaction (PCR) and transcription-mediated amplification (TMA). These tests amplify and detect the genetic material of the bacteria, offering high sensitivity and specificity. However, these methods often require specialized laboratories and trained personnel, making them less accessible and delaying results.

Key Market Drivers

Rising Prevalence of Chlamydia Infections is Driving Chlamydia Infection Diagnostics Market

In recent years, the global healthcare landscape has witnessed a significant increase in the prevalence of Chlamydia infections, propelling the growth of the Chlamydia infection diagnostics market. Chlamydia is one of the most common sexually transmitted infections (STIs) globally, affecting millions of individuals each year. The rising incidence of this infection has brought to light the critical need for accurate and timely diagnostics, leading to the expansion of the diagnostics market focused on Chlamydia infections. Chlamydia trachomatis, the bacterium responsible for causing Chlamydia infections, primarily affects the genital tract but can also manifest in the eyes and respiratory system. The infection is often asymptomatic, which makes its early detection and diagnosis challenging. If left untreated, Chlamydia infections can result in severe complications, such as pelvic inflammatory disease (PID) in women, leading to infertility, ectopic pregnancy, and chronic pain. In men, untreated Chlamydia infections can lead to epididymitis, which can cause testicular pain and, in rare cases, infertility. The driving force behind the growth of the Chlamydia infection diagnostics market is the alarming increase in the prevalence of Chlamydia infections across all age groups. Young adults and adolescents are particularly susceptible due to their higher likelihood of engaging in risky sexual behaviors and their limited awareness of the importance of safe sex practices and regular screening. Additionally, changing cultural attitudes toward sex and relationships, as well as the stigma associated with discussing and testing for STIs, further contribute to the underdiagnosis and underreporting of Chlamydia infections. To combat the rising prevalence of Chlamydia infections, healthcare systems and organizations are emphasizing the importance of regular screening, especially for sexually active individuals and those with multiple partners. This emphasis on early detection and treatment has sparked a surge in demand for reliable and accurate Chlamydia infection diagnostics. Consequently, the market has witnessed the development of innovative diagnostic technologies and tools to enable efficient and convenient testing.

Recent data underscores this trend. According to the World Health Organization (WHO), in 2020, an estimated 129 million new cases of Chlamydia trachomatis infection occurred worldwide among adults aged 15 to 49 years. The global prevalence among people aged 15–49 years was estimated to be 4.0% for women and 2.5% for men in 2020. Furthermore, a meta-analysis published in 2025 found the global prevalence of Chlamydia trachomatis genital infection in pregnant women to be 8.4%. These statistics highlight the substantial burden of Chlamydia infections globally and the critical need for effective diagnostic solutions.

Increasing Focus on Women's Health is Driving Chlamydia Infection Diagnostics Market

​The growing emphasis on women's health has significantly influenced the approach to managing Chlamydia infections. A deeper understanding of the unique health challenges faced by women has highlighted the importance of early detection and management of such infections to prevent long-term complications. Medical research and advocacy have underscored disparities in healthcare outcomes between genders, prompting healthcare systems to prioritize women's health concerns. Consequently, there is heightened awareness about the significance of routine screenings for Chlamydia, especially among sexually active women. Advancements in diagnostic technologies have facilitated more accurate and accessible detection methods, enabling timely interventions. Healthcare providers are increasingly proactive in recommending regular screenings, aligning with government policies and guidelines that stress the importance of STI testing among vulnerable populations, including young and pregnant women. Ongoing research continues to enhance the understanding of Chlamydia infections, leading to the development of improved diagnostic tools and treatment options.​

Recent statistics underscore the urgency of addressing Chlamydia infections among women. According to the Centers for Disease Control and Prevention (CDC), in 2023, there were over 1.6 million reported cases of Chlamydia in the United States, with the majority occurring in women under the age of 25. Specifically, women aged 15–24 years accounted for approximately 43.4% of all incident Chlamydia infections, highlighting the need for targeted screening and prevention efforts in this demographic.

Furthermore, data from the CDC indicates that the rate of Chlamydia among women aged 15–24 was 8,219 per 100,000 population, significantly higher than in other age groups. These figures emphasize the critical need for continued public health initiatives focused on education, routine screening, and early treatment to mitigate the impact of Chlamydia infections on women's health.

Download Free Sample Report

Key Market Challenges

Underdiagnosis and Lack of Awareness

One of the primary challenges in the Chlamydia infection diagnostics market is the widespread underdiagnosis resulting from asymptomatic presentations of the disease. Chlamydia is often termed a "silent" infection because the majority of infected individuals—especially women—do not experience noticeable symptoms. As a result, they may not seek medical attention or testing, allowing the infection to persist undetected. This contributes to a large pool of undiagnosed cases, which not only increases the risk of long-term complications such as pelvic inflammatory disease, infertility, and ectopic pregnancies but also facilitates the continued transmission of the infection within the community.

Another significant barrier is the lack of awareness and education around sexually transmitted infections (STIs) like Chlamydia. Many individuals, particularly adolescents and young adults, are unaware of the risks associated with unprotected sexual activity and the importance of regular STI screening. Cultural taboos and stigma surrounding sexual health discussions further discourage people from seeking testing. In some cases, even healthcare providers may not routinely recommend Chlamydia screening, especially in settings where resources are limited or STI awareness is low. These socio-cultural and systemic issues result in low testing uptake, underutilization of available diagnostic tools, and delayed treatment.

Need for Enhanced Screening Programs

One of the significant challenges in the Chlamydia infection diagnostics market is the pressing need to enhance and expand current screening programs. Presently, most screening efforts are focused on high-risk groups, particularly sexually active young adults aged 15–24. While this approach addresses a segment with elevated infection rates, it inadvertently overlooks other at-risk populations, such as older adults, men who do not frequently engage with healthcare services, or asymptomatic carriers who may not be aware they are infected. The asymptomatic nature of Chlamydia in many individuals compounds this issue, allowing the infection to persist and spread undetected within the community.

A more inclusive and strategic approach to screening is crucial for early detection and intervention. Public health systems often struggle with limited resources, making it difficult to scale up diagnostics across diverse population groups. Geographic disparities, particularly in rural or underserved regions, also hinder access to testing facilities. Additionally, social stigma and lack of awareness about STIs further discourage individuals from seeking timely screening. As a result, many cases go undiagnosed and untreated, contributing to long-term complications such as pelvic inflammatory disease, infertility, and increased risk of HIV transmission.

Key Market Trends

Technological Advancements

One of the most significant developments in Chlamydia infection diagnostics is the advent of nucleic acid amplification techniques (NAATs). These methods involve the amplification of Chlamydia-specific nucleic acids (DNA or RNA) to detect the presence of the bacterium even at low concentrations. NAATs, such as polymerase chain reaction (PCR), ligase chain reaction (LCR), and loop-mediated isothermal amplification (LAMP), offer high sensitivity and specificity, enabling early and accurate detection of Chlamydia infections. These techniques have revolutionized diagnostic accuracy, reducing false negatives and improving patient outcomes. In recent years, the ubiquity of smartphones has been harnessed to advance Chlamydia infection diagnostics. Researchers have developed smartphone-based diagnostic platforms that use the phone's camera and processing capabilities to analyze test results. Users can capture images of diagnostic test strips or devices, and specialized software interprets the results. This approach not only enhances accessibility but also reduces the need for specialized equipment and training. Smartphone-based diagnostics have the potential to empower individuals to monitor their health in the comfort of their own homes. While nucleic acid-based diagnostics are highly sensitive, they primarily detect active infections. Serological and antibody-based assays focus on identifying the body's immune response to Chlamydia infection. These assays measure the presence of antibodies produced in response to the infection, providing insights into both current and past infections. Serological tests are particularly useful for epidemiological studies and identifying individuals with a history of Chlamydia exposure. Combining nucleic acid-based and serological approaches offers a comprehensive picture of an individual's infection history and status.

Segmental Insights

Test Type Insights

Based on the Test Type, Nucleic Acid Amplification Test (NAAT) emerged as the dominant segment in the Global Chlamydia Infection Diagnostics Market in 2024. Nucleic Acid Amplification Test (NAAT) is a powerful molecular technique designed to amplify and detect specific sequences of DNA or RNA within a biological sample. The primary purpose of NAAT is to identify the presence of pathogens, such as bacteria, viruses, and fungi, by amplifying their genetic material to levels detectable by modern laboratory equipment. This method is incredibly sensitive, enabling the detection of even a few copies of the target nucleic acid sequence.

Type of Infections Insights

Based on the Type of Infections, Genital Chlamydia Infection emerged as the dominant segment in the Global Chlamydia Infection Diagnostics Market in 2024. Genital chlamydia infection, caused by the bacterium Chlamydia trachomatis, is one of the most common sexually transmitted infections (STIs) worldwide. This infection can affect both men and women, often showing mild or no symptoms initially, but if left untreated, it can lead to serious health complications. Education about the causes, symptoms, testing, treatment, and prevention of genital chlamydia is crucial to controlling its spread and minimizing its impact on public health. 

Download Free Sample Report

Regional Insights

North America emerged as the dominant region in the Global Chlamydia Infection Diagnostics Market in 2024. This is attributed to the region's cutting-edge technological advancements. Polymerase chain reaction (PCR) and nucleic acid amplification tests (NAATs) have revolutionized diagnostic accuracy. These techniques amplify the genetic material of the bacteria, allowing even small traces of the infection to be detected. North American laboratories and research institutions have led the way in refining these diagnostic methods, increasing their sensitivity, specificity, and speed. The region's advanced healthcare infrastructure also plays a pivotal role in Chlamydia infection diagnostics. North America boasts a well-developed healthcare system with widespread access to medical facilities, testing centers, and professional healthcare providers. This accessibility enables individuals to seek medical attention and get tested promptly. Moreover, public health initiatives and educational campaigns raise awareness about the importance of regular testing, further contributing to early detection and diagnosis.

Asia-Pacific has emerged as the fastest-growing region in the Global Chlamydia Infection Diagnostics Market, driven by significant demographic, healthcare, and economic factors. The rapid population growth and increasing urbanization in countries such as China, India, and Southeast Asian nations have led to greater awareness of sexually transmitted infections (STIs) and an enhanced demand for diagnostic solutions. As more people in these regions engage in sexual activity at younger ages and with multiple partners, the incidence of Chlamydia infections has surged, particularly among young adults. In response, governments and health organizations have increasingly emphasized STI prevention and early detection. This has created a substantial opportunity for diagnostic companies to expand their presence and offer advanced solutions in a region that historically had limited access to such services. Moreover, public health campaigns and educational initiatives are raising awareness about the importance of early testing and treatment, which is further boosting the demand for Chlamydia infection diagnostics.

Recent Developments

• In January 2025, Binx Health, a healthcare technology and diagnostics company, revealed key findings from a Massachusetts General Hospital (MGH) study evaluating the real-world effectiveness of Point of Care (POC) testing for Chlamydia trachomatis (CT) and Neisseria gonorrhoeae (NG) in symptomatic patients at a sexual health clinic.
• In January 2025, Roche announced that the U.S. Food and Drug Administration (FDA) granted 510(k) clearance and Clinical Laboratory Improvement Amendments (CLIA) waiver for its cobas liat STI multiplex assay panels. The panels, which include tests for chlamydia and gonorrhea (CT/NG), as well as chlamydia, gonorrhea, and Mycoplasma genitalium (CT/NG/MG), allow clinicians to diagnose multiple STIs from a single sample. These tests will initially be available in the U.S. with CE mark commercialization expected soon thereafter.
• In October 2024, Quest Diagnostics, a leader in diagnostic services, introduced a new service to enhance convenience and speed in testing and treating common genital tract infections (GTIs). Quest is the first laboratory provider to offer patients experiencing vaginitis and similar GTI symptoms the option to self-collect a swab specimen nationwide, supporting patient care and promoting greater choice and empowerment in healthcare.
• In August 2023, The USA is set to introduce a previously used antibiotic as a preventive pill in its ongoing efforts to enhance its fight against sexually transmitted infections (STIs).The utilization of DoxyPEP, also known as doxycycline, subsequent to unprotected sexual activity, has demonstrated a noteworthy reduction in the likelihood of contracting chlamydia, gonorrhea, and syphilis.
• In February 2023, Thermo Fisher Scientific launched the Applied Biosystems TrueMark STI Select Panel, a PCR-based research test designed to detect Chlamydia trachomatis, Neisseria gonorrhoeae, Trichomonas vaginalis, and Mycoplasma genitalium in a single test. The panel also includes RNase P as a human internal control.

Key Market Players

• F. Hoffmann-La Roche Ltd.
• Abbott Laboratories
• Hologic, Inc.
• Becton, Dickinson and Company
• Bio-Rad Laboratories, Inc
• Quidel Corporation
• DiaSorin SpA
• AstraZeneca
• Teva Pharmaceutical Industries Limited
• bioMérieux SA

 Report Scope:

In this report, the Global Chlamydia Infection Diagnostics Market has been segmented into the following categories, in addition to the industry trends which have also been detailed below:

            ·         Chlamydia Infection Diagnostics Market, By Test Type:

o   Culture Test

o   Nucleic Acid Amplification Test (NAAT)

o   Direct Fluorescent Antibody Test

o   Serology Test

o   Other

            ·         Chlamydia Infection Diagnostics Market, By Type of Infections:

o   Genital Chlamydia Infection

o   Rectal Chlamydia Infection

o   Ocular Chlamydia Infection

            ·         Chlamydia Infection Diagnostics Market, By End User:

o   Hospitals

o   Specialty Clinics

o   Diagnostics Centre

            ·         Chlamydia Infection Diagnostics Market, By Region:

o   North America

o   Asia-Pacific

o   Europe

o   Middle East & Africa

o   South America

Competitive Landscape

Company Profiles: Detailed analysis of the major companies present in the Global Chlamydia Infection Diagnostics Market.

Available Customizations:

Global Chlamydia Infection Diagnostics Market report with the given market data, TechSci Research offers customizations according to a company's specific needs. The following customization options are available for the report:

Company Information

• Detailed analysis and profiling of additional market players (up to five).

Global Chlamydia Infection Diagnostics Market is an upcoming report to be released soon. If you wish an early delivery of this report or want to confirm the date of release, please contact us at sales@techsciresearch.com